New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
11:12 EDTNWL, NVS, TSRA, SGMO, XPOHigh option volume stocks: SGMO NVS XPO TSRA NWL
News For SGMO;NVS;XPO;TSRA;NWL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
15:02 EDTNVSPiper Jaffray biopharma analyst holds an analyst/industry conference call
Biopharmaceuticals Analyst Schimmer, along with Dr. Diana Do, a leading clinician-scientist who specializes in the treatment of retinal conditions at the University of Nebraska, discuss the current practice dynamics and treatment of wet-AMD (age-related macular degeneration), the recent AAVL Phase 2a dataset and key points of debate and emerging treatment options in wet-AMD on an Analyst/Industry conference call to be held on July 7 at 4:30 pm.
July 1, 2015
07:25 EDTNWLConsumer goods makers challenged by surging freight costs, WSJ reports
Subscribe for More Information
05:16 EDTNVSNovartis division Alcon receives CE Mark for AcryS of IQ Aspheric IOL
Subscribe for More Information
June 30, 2015
08:08 EDTXPOXPO Logistics coverage resumed with an Overweight at Morgan Stanley
Subscribe for More Information
05:32 EDTNVSNovartis launches first Apple Watch app for visually impaired people
Novartis Pharmaceuticals (NVS) announced the release of new features for its ViaOpta applications, and the extension for use with smart watches. The discreet, hands-free nature of using ViaOpta app with wearable devices, such as Apple Watch (AAPL) and Android Wear (GOOG), provides users with an experience that seamlessly fits into their existing routines allowing those with visual impairments to navigate daily life with even greater ease.
June 29, 2015
08:35 EDTNVSAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
05:15 EDTNVSNovartis acquires Spinifex Pharmaceuticals, terms not disclosed
Novartis announced that it has entered into an agreement to acquire Spinifex Pharmaceuticals. Spinifex Pharmaceuticals is a U.S. and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor, or AT2R, antagonist. Financial terms were not disclosed.
June 26, 2015
17:53 EDTXPOXPO Logistics says ND is subject of ongoing investigation by French regulators
XPO Logistics said in a regulatory filing that ND or Norbert Dentressangle is subject to an ongoing investigation by the French Competition Authority. On June 8, XPO Logistics announced that it has consummated the previously announced agreement to purchase all of the shares of Norbert Dentressangle held by Mr. Norbert Dentressangle and his family, representing 67% of the company's outstanding shares, at a price of 217.50 euros per share. XPO continued in a filing: "In July 2014, ND Distribution received notification from the French antitrust authorities relating to alleged anti-competitive practices of companies in the parcel express delivery business. Most French companies participating in this market also received complaints covering several prior years. The investigation focuses on the role played by an industry syndicate, in which the participants are said to have exploited the syndicate’s “Pooling Business Advisory” meetings so as to align their sales practices and, in particular, prices. The French antitrust authorities are reviewing the period from June 2007 to March 2008, which straddles the period during which ND completed its indirect takeover of ND Distribution. ND expects that a hearing may be held late in 2015 or early in 2016. Additionally, ND is involved in certain proceedings in the Valence Criminal Court regarding a two-year preliminary enquiry into the way ND organizes international transport sub-contracting operations. No provision has been made in ND’s financial statements regarding either investigation, and while ND disputes the claims against it, any adverse findings or decisions arising out of such investigation could have a material adverse impact on ND’s business and financial condition. "
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
June 25, 2015
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.
June 23, 2015
12:52 EDTNWLStamps.com receives second request from DOJ for information in PSI acquisition
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use